311 related articles for article (PubMed ID: 11835461)
1. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
[TBL] [Abstract][Full Text] [Related]
2. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Colzi A; Turner K; Lees AJ
J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
[TBL] [Abstract][Full Text] [Related]
3. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
5. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
Stefani A; Stanzione P; Bassi A; Mazzone P; Vangelista T; Bernardi G
J Neural Transm (Vienna); 1997; 104(8-9):895-904. PubMed ID: 9451721
[TBL] [Abstract][Full Text] [Related]
6. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
7. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Grandas FJ; Sesar-Ignacio Á
Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
[TBL] [Abstract][Full Text] [Related]
8. [Candidate patient for subcutaneous apomorphine injection].
Chacón JR; Mata M
Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine: an underutilized therapy for Parkinson's disease.
Poewe W; Wenning GK
Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
[TBL] [Abstract][Full Text] [Related]
10. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Rascol O
Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
12. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.
Cristina S; Zangaglia R; Mancini F; Martignoni E; Nappi G; Pacchetti C
Clin Neuropharmacol; 2003; 26(3):146-50. PubMed ID: 12782917
[TBL] [Abstract][Full Text] [Related]
13. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
14. ['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine].
Jansen EN; van Laar T
Ned Tijdschr Geneeskd; 1990 May; 134(18):889-91. PubMed ID: 2345577
[No Abstract] [Full Text] [Related]
15. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
Vaamonde J; Ibáñez R; Gudín M; Hernández A
Neurologia; 2003 Apr; 18(3):162-5. PubMed ID: 12677484
[TBL] [Abstract][Full Text] [Related]
16. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
Koller W; Stacy M
Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
[TBL] [Abstract][Full Text] [Related]
17. Rapid treatment of "wearing off" in Parkinson's disease.
Swope DM
Neurology; 2004 Mar; 62(6 Suppl 4):S27-31. PubMed ID: 15037669
[TBL] [Abstract][Full Text] [Related]
18. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
Facca A; Sanchez-Ramos J
Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
[No Abstract] [Full Text] [Related]
19. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
Nutt JG; Carter JH
Neurology; 2000 Jan; 54(1):247-50. PubMed ID: 10636162
[TBL] [Abstract][Full Text] [Related]
20. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]